Select Publications

By Associate Professor Suzanne Jean Hodgkinson

Journal articles

Bishop GA; Li J; Trang G; Hodgkinson SJ; Hall BM; McCaughan GW; Allen RDM; Wang C, 2004, 'POST-TRANSPLANT IL-4 TREATMENT CONVERTS RAT LIVER ALLOGRAFT TOLERANCE TO REJECTION', Transplantation, 78, pp. 153 - 153, http://dx.doi.org/10.1097/00007890-200407271-00404

Tran GT; Hodgkinson SJ; Carter N; Killingsworth M; Spicer ST; Hall BM, 2002, 'Attenuation of experimental allergic encephalomyelitis in complement component 6-deficient rats is associated with reduced complement C9 deposition, P-selectin expression, and cellular infiltrate in spinal cords', Journal of Immunology, 168, pp. 4293 - 4300, http://dx.doi.org/10.4049/jimmunol.168.9.4293

Hodgkinson SJ, 2001, 'Should all patients with an initial diagnosis of multiple sclerosis be treated with beta interferon?', Journal of Clinical Neuroscience, 8, pp. 378 - 379, http://dx.doi.org/10.1054/jocn.2001.0911

Spicer ST; Ha H; Boyd RA; He XY; Carter N; Tran GT; Penny MJ; Hodgkinson SJ; Hall BM, 2001, 'IL-4 Therapy Prevents the development of proteinuria in active Heymann Nephritis by inhibition of Tc1 cells', Journal of Immunology, 167, pp. 3725 - 3733

Tran GT; Carter N; Hodgkinson SJ, 2001, 'Mycophenolate mofetil treatment accelerates recovery from experimental allergic encephalomyelitis', International Immunopharmacology, 1, pp. 1709 - 1723

Tran GT; Carter N; He XY; Spicer ST; Plain KM; Nicolls M; Hall BM; Hodgkinson SJ, 2001, 'Reversal of experimental allergic encephalomyelitis with non-mitogenic, non-depleting anti-CD3 mAB therapy with a preferential effect on Th1 cells that is augmented by IL-4', International Immunology, 13, pp. 1109 - 1120

Hall BM; Hodgkinson SJ; Quin JW, 1999, 'Corticosteroids in Autoimmunity', Australian Prescriber, pp. 15 - 18

Hall BM; Hodgkinson SJ; Quin JW, 1998, 'Corticosteroids in autoimmune diseases.', Australian Prescriber, pp. 9 - 11

Van Oosten BW; Lai M; Hodgkinson S; Barkhof F; Miller DH; Moseley IF; Thompson AJ; Rudge P; McDougall A; McLeod JG; Adèr HJ; Polman CH, 1997, 'Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled, MR- monitored phase II trial', Neurology, 49, pp. 351 - 357, http://dx.doi.org/10.1212/WNL.49.2.351

Murwani R; Hodgkinson S; Armati P, 1996, 'Tumor necrosis factor α and interleukin-6 mRNA expression in neonatal Lewis rat Schwann cells and a neonatal rat Schwann cell line following interferon γ stimulation', Journal of Neuroimmunology, 71, pp. 65 - 71, http://dx.doi.org/10.1016/S0165-5728(96)00131-2

Miller DH; Albert PS; Barkhof F; Francis G; Frank JA; Hodgkinson S; Lublin FD; Paty DW; Reingold SC; Simon J, 1996, 'Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis', Annals of Neurology, 39, pp. 6 - 16, http://dx.doi.org/10.1002/ana.410390104

Van Oosten BW; Lai M; Barkhof F; Miller DH; Moseley IF; Thompson AJ; Hodgkinson S; Polman CH, 1996, 'A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis', Multiple Sclerosis, 1, pp. 339 - 342, http://dx.doi.org/10.1177/135245859600100611

Barkhof F; Thompson AJ; Hodgkinson S; van Oosten B; Lai M; Polman CH; McLeod J; Rudge P; Moseley IF; Ader H, 1995, 'Double-blind, placebo-controlled, MR monitored exploratory trial of chimeric anti-CD4 antibodies in MS.', Journal of Neuroimmunology, 56-63, pp. 15 - 15, http://dx.doi.org/10.1016/0165-5728(95)98902-n

Lindsey JW; Hodgkinson S; Mehta R; Siegel RC; Mitchell DJ; Lim M; Piercy C; Tram T; Dorfman L; Enzmann D; Steinman L, 1994, 'Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis', Neurology, 44, pp. 413 - 419, http://dx.doi.org/10.1212/wnl.44.3_part_1.413

Lindsey RJW; Hodgkinson S; Mehta R; Mitchell D; Enzmann D; Steinman L, 1994, 'Repeated treatment with chimeric anti‐CD4 antibody in multiple sclerosis', Annals of Neurology, 36, pp. 183 - 189, http://dx.doi.org/10.1002/ana.410360210

Hodgkinson SJ; Westland KW; Pollard JD, 1994, 'Transfer of experimental allergic neuritis by intra neural injection of sensitized lymphocytes', Journal of the Neurological Sciences, 123, pp. 162 - 172, http://dx.doi.org/10.1016/0022-510X(94)90219-4

Bell RB; Lindsey JW; Sobel RA; Hodgkinson S; Steinman L, 1993, 'Diverse T cell receptor Vβ gene usage in the central nervous system in experimental allergic encephalomyelitis', Journal of Immunology, 150, pp. 4085 - 4092

Steinman L; Lindsey JW; Alters S; Hodgkinson S, 1993, 'From treatment of experimental allergic encephalomyelitis to clinical trials in multiple sclerosis.', Immunology series, 59, pp. 253 - 260

Smilek DE; Wraith DC; Hodgkinson S; Dwivedy S; Steinman L; McDevitt HO, 1991, 'A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis', Proceedings of the National Academy of Sciences of the United States of America, 88, pp. 9633 - 9637

Knox SJ; Levy R; Hodgkinson S; Bell R; Brown S; Wood GS; Hoppe R; Abel EA; Steinman L; Berger RG; Gaiser C; Young G; Bindl J; Hanham A; Reichert T, 1991, 'Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides', Blood, 77, pp. 20 - 30

Hodgkinson SJ; Pollard JD; McLeod JG, 1990, 'Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy', Journal of Neurology Neurosurgery and Psychiatry, 53, pp. 327 - 330, http://dx.doi.org/10.1136/jnnp.53.4.327

Sakai K; Zamvil SS; Mitchell DJ; Hodgkinson S; Rothbard JB; Steinman L, 1989, 'Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins', Proceedings of the National Academy of Sciences of the United States of America, 86, pp. 9470 - 9474, http://dx.doi.org/10.1073/pnas.86.23.9470

Conference Papers

Lizak N; Sharmin S; Walt AVD; Butzkueven H; Lechner-Scott J; Buzzard K; Skibina O; Hodgkinson S; Slee M; John N; Roos I; Kalincik T, 2024, '3 Managing disease activity during treatment with natalizumab in relapsing-remitting multiple sclerosis', in Young Investigators Session Abstracts, BMJ Publishing Group Ltd, pp. A2.1 - A2, presented at ANZAN Annual Scientific Meeting 2024 Abstracts, http://dx.doi.org/10.1136/bmjno-2024-anzan.3

Roos I; Sharmin S; Malpas C; Lechner-Scott J; Hodgkinson S; Walt AVD; Butzkueven H; Buzzard K; Skibina O; John N; Barnett M; Kalincik T, 2024, '3138 Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis', in Poster Abstracts, BMJ Publishing Group Ltd, pp. A43.1 - A43, presented at ANZAN Annual Scientific Meeting 2024 Abstracts, http://dx.doi.org/10.1136/bmjno-2024-anzan.120

Migocki M; Walt AVD; Butzkueven H; Spelman T; Kermode A; Fabis-Pedrini M; Carroll WM; Lechner-Scott J; John N; Barnett M; Hodgkinson S; McCombe P; Kalincik T; Macdonell R; Slee M; Schmitt B, 2024, '3149 Real-world Australian experience with Ofatumumab in the MSBase registry', in Poster Abstracts, BMJ Publishing Group Ltd, pp. A45.3 - A46, presented at ANZAN Annual Scientific Meeting 2024 Abstracts, http://dx.doi.org/10.1136/bmjno-2024-anzan.127

De Stefano N; Achiron A; Barkhof F; Chan A; Derfuss T; Hodgkinson S; Leocani L; Montalban X; Prat A; Schmierer K; Sellebjerg F; Vermersch P; Wiendl H; Keller B; Smyk A; Gardner L, 2023, 'Early Onset of Action and Sustained Efficacy of MRI Outcomes During Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis: Results of the 2-year MAGNIFY-MS Study (P6-3.018)', in Neurology, Ovid Technologies (Wolters Kluwer Health), http://dx.doi.org/10.1212/wnl.0000000000202977

Wiendl H; De Stefano N; Barkhof F; Montalban X; Achiron A; Derfuss T; Chan A; Hodgkinson S; Prat A; Leocani L; Schmierer K; Sellebjerg F; Vermersch P; Jin H; Jarvinen E; Chudecka A; Gardner L, 2023, 'Blood Biomarker Dynamics in Highly Active Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study', in NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, MA, Boston, presented at 75th Annual Meeting of the American-Academy-of-Neurology (AAN), MA, Boston, 22 April 2023 - 27 April 2023, http://dx.doi.org/10.1212/WNL.0000000000202961

Hardy T; Aouad P; Barnett M; Blum S; Broadley S; Carroll W; Crimmins D; Griffiths D; Hodgkinson S; Lechner-Scott J; Lee A; Malhotra R; McCombe P; Parratt J; Plummer C; Walt AVD; Martel K; Walker R, 2023, '2723 Secondary progressive multiple sclerosis patients in Australia treated with siponimod; novel real-world evidence from the MSGo digital support program', in Poster Abstract, BMJ Publishing Group Ltd, pp. A41.2 - A41, presented at ANZAN Annual Scientific Meeting 2023 Abstracts, http://dx.doi.org/10.1136/bmjno-2023-anzan.113

Hardy T; Aouad P; Barnett M; Blum S; Broadley S; Carroll W; Crimmins D; Griffiths D; Hodgkinson S; Lechner-Scott J; Lee A; Malhotra R; McCombe P; Parratt J; Plummer C; Van der Walt A; Martel K; Walker R, 2023, 'Novel Real World Evidence from MSGo, a Digital Support Program for Secondary Progressive Multiple Sclerosis Patients in Australia using Siponimod', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, pp. NP44 - NP46

Diouf I; Malpas CB; Sharmin S; Skibina O; Buzzard K; Lechner-Scott J; Barnett M; Hodgkinson S; Slee M; Butler E; McCombe P; van der Walt A; Butzkueven H; Vucic S; Macdonell R; Shaw C; Kalincik T, 2022, 'Comparison of multiple disease modifying therapies in multiple sclerosis with marginal structural models', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, AUSTRALIA, Hobart, pp. 5 - 6, presented at MS Australia Progress in MS Research Scientific Conference, AUSTRALIA, Hobart, 04 April 2022 - 05 April 2022

Sharmin S; Malpas C; Lechner-Scott J; Slee M; McCombe P; Vucic S; Butler E; Hodgkinson S; Barnett M; Skibina O; van der Walt A; Buzzard K; Shaw C; Kermode A; Taylor B; Shuey N; Macdonell R; Butzkueven H; Kalincik T, 2022, 'Confirmed disability progression as a marker of permanent disability in multiple sclerosis', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, AUSTRALIA, Hobart, pp. 8 - 8, presented at MS Australia Progress in MS Research Scientific Conference, AUSTRALIA, Hobart, 04 April 2022 - 05 April 2022

Roos I; Malpas CB; Leray E; Buzzard K; Skibina O; Lechner-Scott J; McCombe P; Slee M; Butler E; Macdonell R; van der Walt A; Hodgkinson S; Barnett M; Vucic S; Vukusic S; Butzkueven H; Kalincik T, 2022, 'Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, AUSTRALIA, Hobart, pp. 6 - 7, presented at MS Australia Progress in MS Research Scientific Conference, AUSTRALIA, Hobart, 04 April 2022 - 05 April 2022

Zhong M; van der Walt A; Hodgkinson S; Kalincik T; Izquierdo G; Eichau S; Grand'Maison F; Lechner-Scott J; Buzzard K; Skibina O; Butler E; Prevost J; McCombe P; Van Pesch V; Oh J; Butzkueven H; Jokubaitis V, 2022, 'Time to relapse after switching to cladribine is predicted by relapse during the washout period', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, AUSTRALIA, Hobart, pp. 11 - 11, presented at MS Australia Progress in MS Research Scientific Conference, AUSTRALIA, Hobart, 04 April 2022 - 05 April 2022

Hardy T; Aouad P; Blum S; Broadley S; Carroll W; Crimmins D; Griffiths D; Hodgkinson S; Lechner-Scott J; Lee A; Malhotra R; Parratt J; Plummer C; Walt AVD; Walker R, 2022, '2258 Novel generation of real-world evidence through MSGo, a digital support program supporting the use of siponimod in secondary progressive multiple sclerosis patients in Australia', in Abstracts, BMJ Publishing Group Ltd, pp. A25.1 - A25, presented at ANZAN Annual Scientific Meeting 2022 Abstracts, http://dx.doi.org/10.1136/bmjno-2022-anzan.64

Vitkova M; Diouf I; Malpas C; Barnett M; Hodgkinson S; Butler E; Slee M; Taylor B; Butzkueven H; Lechner-Scott J; McCombe P; Vucic S; Macdonell R; Shaw C; Kalincik T, 2022, '2327 Latitude, UVR and multiple sclerosis severity', in Abstracts, BMJ Publishing Group Ltd, pp. A11.3 - A12, presented at ANZAN Annual Scientific Meeting 2022 Abstracts, http://dx.doi.org/10.1136/bmjno-2022-anzan.29

Maltby VE; Lea RA; Monif M; Fabis-Pedrini MJ; Buzzard K; Kalincik T; Kermode AG; Taylor B; Hodgkinson S; McCombe P; Osborne M; Butzkueven H; Barnett M; Lechner-Scott J, 2022, 'Cladribine: a multicentre, LOng-term efficacy and Biomarker Australian Study (CLOBAS)', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, pp. 26 - 26

Roos I; Malpas CB; Leray E; Buzzard K; Skibina O; Lechner-Scott J; McCombe P; Slee M; Butler E; Macdonell R; van der Walt A; Hodgkinson S; Barnett M; Vucic S; Vukusic S; Butzkueven H; Kalincik T, 2022, 'Disease reactivation after cessation of diseasemodifying therapy in relapsing-remitting multiple sclerosis', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, pp. 6 - 7

Diouf I; Malpas CB; Sharmin S; Skibina O; Buzzard K; Lechner-Scott J; Barnett M; Hodgkinson S; Slee M; Butler E; McCombe P; van der Walt A; Butzkueven H; Vucic S; Macdonell R; Shaw C; Kalincik T, 2022, 'Variability of the response to immunotherapy among sub-groups of patients with multiple sclerosis', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, pp. 7 - 7

Yeh WZ; Widyastuti PA; Walt AVD; Stankovich J; Havrdova EK; Horakova D; Vodehnalova K; Ozakbas S; Eichau S; Duquette P; Kalincik T; Patti F; Boz C; Terzi M; Yamout B; Lechner-Scott J; Sola P; Skibina O; Barnett M; Onofrj M; Sá MJ; McCombe P; Grammond P; Ampapa R; Grand’Maison F; Bergamaschi R; Spitaleri DLA; Pesch VV; Cartechini E; Hodgkinson S; Soysal A; Saiz A; Gresle M; Uher T; Maimone D; Turkoglu R; Hupperts RMM; Amato MP; Granella F; Oreja-Guevara C; Altintas A; Macdonell R; Castillo-Trivino T; Butzkueven H; Alroughani R; Jokubaitis VG; Registry M, 2021, '004 Pregnancy-related relapse in natalizumab, fingolimod and dimethyl fumarate-treated women with multiple sclerosis', in Oral abstracts, BMJ Publishing Group Ltd, pp. A2.1 - A2, presented at ANZAN Annual Scientific Meeting 2021 Abstracts, http://dx.doi.org/10.1136/bmjno-2021-anzan.4

Diouf I; Malpas CB; Sharmin S; Skibina O; Buzzard K; Lechner-Scott J; Barnett M; Hodgkinson S; Slee M; Butler E; McCombe P; Walt AVD; Butzkueven H; Vucic S; Macdonell R; Shaw C; Kalincik T, 2021, '006 Comparison of multiple disease modifying therapies in multiple sclerosis with marginal structural models', in Oral abstracts, BMJ Publishing Group Ltd, pp. A3.1 - A3, presented at ANZAN Annual Scientific Meeting 2021 Abstracts, http://dx.doi.org/10.1136/bmjno-2021-anzan.6

Roos I; Malpas CB; Leray E; Buzzard K; Skibina O; Lechner-Scott J; McCombe P; Slee M; Butler E; Macdonell R; Walt AVD; Hodgkinson S; Barnett M; Vucic S; Vukusic S; Butzkueven H; Kalincik T, 2021, '008 Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis', in Oral abstracts, BMJ Publishing Group Ltd, pp. A4.1 - A4, presented at ANZAN Annual Scientific Meeting 2021 Abstracts, http://dx.doi.org/10.1136/bmjno-2021-anzan.8

Butzkueven H; Spelman T; Kalincik T; Buzzard K; Walt AVD; Lechner-Scott J; Hodgkinson S; Butler E; Macdonell R; Slee M; Group MS; Marcel B, 2021, '010 Real-world experience with ocrelizumab in the MSBase registry – Australian RRMS cohort', in Oral abstracts, BMJ Publishing Group Ltd, pp. A4.3 - A5, presented at ANZAN Annual Scientific Meeting 2021 Abstracts, http://dx.doi.org/10.1136/bmjno-2021-anzan.10

Yeh W; Widyastuti P; Van der Walt A; Stankovich J; Gresle M; Havrdova E; Horakova D; Vodehnalova K; Ozakbas S; Eichau S; Duquette P; Kalincik T; Patti F; Boz C; Terzi M; Yamout B; Lechner-Scott J; Sola P; Skibina O; Barnett M; Onofrj M; Sa MJ; Mccombe P; Grammond P; Ampapa R; Grand'Maison F; Bergamaschi R; Spitaleri D; Van Pesch V; Cartechini E; Hodgkinson S; Soysal A; Saiz A; Uher T; Maimone D; Turkoglu R; Hupperts R; Amato MP; Granella F; Oreja-Guevara C; Altintas A; Macdonell R; Castillo-Trivino T; Butzkueven H; Alroughani R; Jokubaitis V, 2020, 'Pregnancy in a modern day multiple sclerosis cohort: predictors of relapse during pregnancy', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, ELECTR NETWORK, pp. 30 - 31, presented at 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), ELECTR NETWORK, 11 September 2020 - 13 September 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000596547100057&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Butzkueven H; Spelman T; Hodgkinson S; Kalincik T; Buzzard K; Skibina O; Eichau Madueno S; Izquierdo G; Van der Walt A; Grand-Maison F; Butler E; Prevost J; Mccombe P; Oh J; Macdonell R; Lechner-Scott J; Van Pesch V; Duquette P; Prat A; Girard M; Kermode A; Fabris J, 2020, 'Real-world experience with cladribine tablets in the msbase registry', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, ELECTR NETWORK, pp. 549 - 549, presented at 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), ELECTR NETWORK, 11 September 2020 - 13 September 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000596547101671&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

De Stefano N; Achiron A; Barkhof F; Chan A; Derfuss T; Hodgkinson S; Leocani L; Montalbant X; Pratt A; Schmierer K; Sellebjerg F; Vermersch P; Wiendl H; Keller B; Roy S, 2020, 'A 2-year Study to Evaluate the Onset of Action of Cladribine Tablets in Subjects with Highly Active Relapsing Multiple Sclerosis: Results from MAGNIFY- MS Baseline Analysis', in EUROPEAN JOURNAL OF NEUROLOGY, WILEY, ELECTR NETWORK, pp. 685 - 686, presented at 6th Congress of the European-Academy-of-Neurology (EAN), ELECTR NETWORK, 23 May 2020 - 26 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000534616801566&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Malpas CB; Roos I; Sharmin S; Butzkueven H; Kappos L; Patti F; Alroughani R; Horakova D; Havrdova EK; Izquierdo G; Eichau S; Hodgkinson S; Grammond P; Lechner-Scott J; Kalincik T, 2019, 'Disease reactivation following fingolimod cessation', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, SWEDEN, Stockholm, pp. 330 - 331, presented at 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, SWEDEN, Stockholm, 11 September 2019 - 13 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000485303101223&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Butzkueven H; Spelman T; Patti F; Eichau S; Grand'Maison F; Kalincik T; Hodgkinson S; Skibina O; Butler E, 2019, 'Real-world experience with Cladribine in the MSBase Registry', in MULTIPLE SCLEROSIS JOURNAL, SAGE PUBLICATIONS LTD, SWEDEN, Stockholm, pp. 326 - 327, presented at 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, SWEDEN, Stockholm, 11 September 2019 - 13 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000485303101217&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page

Filter by type

View all »

ORCID as entered in ROS

https://orcid.org/0000-0002-9029-6663